Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf MedicamentfiledCriticalPf Medicament
Priority to ARP070105218priorityCriticalpatent/AR063926A1/en
Publication of AR063926A1publicationCriticalpatent/AR063926A1/en
Anticuerpos aislados, o los compuestos derivados o fragmentos funcionales de los mismos, capaces de inhibir la proliferación de células tumorales in vitro y/o in vivo, dichos anticuerpos han sido obtenidos por tamizado funcional. Más particularmente, se relaciona con el anticuerpo 6F4, específico para la proteína JAM-A, como así también con su uso para el tratamiento del cáncer. También están cubiertas las composiciones farmacéuticas compuestas por tales anticuerpos. Reivindicación 1: Un anticuerpo aislado, o un compuestos derivado o fragmento funcional del mismos, capaz de inhibir la proliferación de células tumorales in vitro y/o in vivo, caracterizado porque comprende al menos una RDC elegida entre las secuencias de RsDC que comprenden al menos las SEC ID N°: 1, 2, 3, 4, 5 o 6 o por lo menos una RDC cuya secuencia tien por lo menos una identidad de 80% luego de la alineación óptima con las secuencias SEC ID N°: 1, 2, 3, 4, 5 o 6.Isolated antibodies, or the derivative compounds or functional fragments thereof, capable of inhibiting the proliferation of tumor cells in vitro and / or in vivo, said antibodies have been obtained by functional screening. More particularly, it relates to the 6F4 antibody, specific for the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies are also covered. Claim 1: An isolated antibody, or a derivative compound or functional fragment thereof, capable of inhibiting the proliferation of tumor cells in vitro and / or in vivo, characterized in that it comprises at least one RDC chosen from the RsDC sequences comprising at least SEQ ID N °: 1, 2, 3, 4, 5 or 6 or at least one RDC whose sequence has at least an 80% identity after optimal alignment with the sequences SEQ ID N °: 1, 2 , 3, 4, 5 or 6.
"antibody or antigen binding fragment thereof which specifically binds to cd37, immunoconjugate comprising them, use of said antibody, fragment and immunoconjugate, composition comprising them, kit, isolated cell, as well as in vitro method for inhibiting growth" of a cell expressing cd37 "
Compounds derived from 1,2,5-oxadiazoles, indolamine 2,3-dioxygenase inhibitors; pharmaceutical composition; process to prepare them; and its use for the treatment of cancer, viral infection, depression, neurodegenerative disorder, trauma, cataracts, organ transplant rejection, autoimmune diseases, among others.
Compounds derived from substituted pyrazolopyridine; pharmaceutical composition comprising them; method of preparation of the compounds, intermediates; and their use in the treatment of diseases, such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others.
Compounds derived from n-substituted piperidinyl 4-arylsulfonamides, which act as modulators of the sfrp-1 protein; process to prepare the compounds; pharmaceutical composition comprising said co-compounds and use of the compounds to prepare medicaments for the treatment of diseases.
Compounds derived from pyrazole-pyridinone; preparation process of said compounds; pharmaceutical composition that includes them; and its use to treat inflammation, paget disease, osteoarthritis, Alzheimer's, among other diseases.